republic of turkey prime ministry

20
REPUBLIC OF TURKEY PRIME MINISTRY Investment Support and Promotion Agency of Turkey ISPAT Pharmaceutical Sector and PPP Projects in Turkey” Derun ÜLGEN Direttore di Progetto Senior

Upload: derica

Post on 29-Jan-2016

50 views

Category:

Documents


0 download

DESCRIPTION

REPUBLIC OF TURKEY PRIME MINISTRY. Investment Support and Promotion Agency of Turkey ISPAT. “ Pharmaceutical Sector and PPP Projects in Turkey ” Derun ÜLGEN Direttore di Progetto Senior. The Turkish pharmaceutical sector is the 6 th largest in Europe in terms of sales. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: REPUBLIC OF TURKEY PRIME MINISTRY

REPUBLIC OF TURKEY PRIME MINISTRY

Investment Support and Promotion Agency of TurkeyISPAT

“Pharmaceutical Sector and PPP Projects in Turkey”

Derun ÜLGENDirettore di Progetto Senior

Page 2: REPUBLIC OF TURKEY PRIME MINISTRY

Top 20 Countries According to Pharmaceutical Sales in 2012

Source: EIU

Great progress has been made in the sector during the last decade and thanks to a series of reforms, the quality and efficiency of the public and private healthcare system have been increased.

Turkey was the 6th largest pharmaceutical market in Europe and 16th largest in the world in 2012 with USD 12.5 billion sales, which means a growth of nearly 10% between 2003 and 2012 and it is expected to grow by 7%-10% each year

The Turkish pharmaceutical sector is the 6th largest in Europe in terms of sales

Page 3: REPUBLIC OF TURKEY PRIME MINISTRY

Healthcare and Pharmaceutical Spending Growth by Region, 2013 Forecasts

According to EIU forecasts, global healthcare and pharmaceutical spending is expected to increase

in 2013 compared to the previous year by 2.4% and 4.0%, respectively, whereas in Turkey, forecasts

indicate higher growth rates than global ones. Within this context, the healthcare sector is expected

to grow by 5.8% and pharmaceutical sector by 8.9%, in 2013.

Global and Turkish pharmaceutical sector will grow

Turkey’s pharmaceutical sales grew 9.7% from

2003 to 2012. This is expected to increase of

8.8% from 2012 to 2017 surpassing USD 19

billion.

Page 4: REPUBLIC OF TURKEY PRIME MINISTRY

Turkey’s pharmaceutical exports increased 10% from 2007 to 2012, surpassing USD 720 million.

For the export values, top ten countries had over 55% of the total export share. Germany is a

prominent partner of Turkey with 10% in 2012, followed by Iraq with 8%, South Korea, which is the

largest export market in Asia, for Turkey, with 7%.

With the help of 2023 Vision Targets, Turkish pharma sector can deliver over USD 13 billion worth of

exports by 2023.

Exports of Pharmaceuticals Sector in Turkey

Pharmaceutical exports

Page 5: REPUBLIC OF TURKEY PRIME MINISTRY

Acquirer Target DateDeal Value

USD MillionsStake

Citibank Venture Capital Ltd; Partners in Life Sciences (PiLS) Biofarma Pharmaceuticals Co. Ltd. 2006 200 100%

White Swan Corporation B.V. Taymed Saglik Urunleri Ticaret Ltd Sti 2006 N/A 100%

Partners in Life Sciences (PiLS) Munir Sahin llac Sanayi ve Ticaret A.S. 2006 22 100%

International Pharma Ltd. Deva Holding AS 2006 50.2 18%

Actavis Group hf (formerlyPharmaco hf ) Fako Ilaclari As 2006 20.4 10%

Eastpharma Holding Saba Ilac Sanayii ve Ticaret A.S. 2007 10 96%

Zentiva NV Eczacıbaşı-Zentiva Kim. Ur. San. ve Tic. A.S. Eczacıbaşı-Zentiva Sag. Urun. San. ve Tic. A.S. 2007 602 75%-75%

Sandoz International GmbH Roche Holding AG (Gebze production plant) 2007 N/A 100%

Eczacıbaşı Ilaç Monrol Nükleer Ürünler 2008 43.1 50%

İş Girişim Sermayesi Dr. F. Frik Ilaç Sanayi 2008 13.4 17%

Partners in Life Sciences Betasan Pharmaceuticals 2008 N/A 100%

Recordati SpA Yeni Ilac 2008 60 100%

Ebewe Pharma EBV Limited 2008 N/A 100%

Zentiva NV Eczacıbaşı-Zentiva Kim. Ur. San. ve Tic. A.S. Eczacıbaşı-Zentiva Sag. Urun. San. ve Tic. A.S. 2009 N/A 25%-25%

Alliance Boots Hedef Alliance Holding 2010 N/A 10%

Polpharma Cenovapharma 2011 N/A 77%

NBK Dem Ilaç 2012 N/A N/A

Amgen Mustafa Nevzat Ilaç 2012 669 96%

M&A market with USD 1.7 billion worth of transactions since 2006

Page 6: REPUBLIC OF TURKEY PRIME MINISTRY

Top 10 Pharmaceutical Manufacturing Companies in Turkey

# Company Market Share (2012)

1 Abdi Ibrahim 7.5% 2 Novartis 7.0%3 Sanofi 5.8%4 Bilim 4.9%5 Pfizer 4.3%6 Bayer 4.3%7 Eastpharma 3.8%8 Glaxo 3.7%9 Roche 3.4%

10 AstraZeneca 3.0%Top Ten Total 47.6%

Turkey has the necessary knowledge base, skilled workforce, infrastructure and geostrategic location to attract global pharmaceutical R&D and could become a global player in the pharma industry.

Strong production facility infrastructure; 76% of drugs consumed in Turkey on a box basis and 49% on a value basis are locally produced.

Under current budget framework, Turkey’s local pharma production will reach 23.3 billion USD by 2023 through the production of innovative and technologically advanced products (as compared to local

production of USD 5 billion USD in 2011).

Industrial employment includes approx.25.000 people

Page 7: REPUBLIC OF TURKEY PRIME MINISTRY

Foreign companies play an important role in manufacturing phase

Multinationals with manufacturing facilities that operate in Turkey include Sanofi, Baxter, Bayer, GSK, Novartis, Pfizer and Roche, with the most recent foreign entrant on the market being EastPharma. Leading multinationals such as Pfizer, Novartis, Bayer and Roche command market shares of 4-6% each. Baxter runs a 50:50 JV with Eczacıbaşı.

International companies are represented by the Pharmaceutical Manufacturers Association of Turkey (IEIS)has 60 members, which also includes domestic firms.

Page 8: REPUBLIC OF TURKEY PRIME MINISTRY

Turkish Drug and Medical Device Institution, a part of the MoH, is in charge of the regulation and control of pharmaceutical prices.

The data protection liability generated by TRIPS entered Turkey’s regulations in March of 1995. In this context all of the confidentiality of information submitted for the purpose of obtaining a license is protected. With this development, laws that are related to data protection in Turkey got closer to standards in Europe.

Regulation

Page 9: REPUBLIC OF TURKEY PRIME MINISTRY

Clinical research

• Turkish Drug and Medical Device Institution is the regulatory authority in drug discovery and R&D and monitors clinical research and R&D activities in Turkey. The institution has prepared a legislation related on Clinical Research in August 2011, which is compatible with European Union directives.

• Turkey is ranked as the 35th country in number of clinical research conducted in the world and 19th in Europe. Turkey conducted over 1,200 clinical researches in 2013 and took a share of 0.6% in total clinical research conducted in the world.

• Companies who want to conduct research in following areas must take permission from Ministry of Health:

• Pharmaceuticals, medical products, herbal medical products that will be tested on human subjects; observational pharmaceutical studies; bioavailability and bioequivalence studies; observational medical device studies and medical device clinical research; stem cell transplantation research; organ and tissue transplantation etc

• One of the goals of the government is to increase R&D spending in the sector to 3% og GDP, thus, in turn it aims to increase the total number of clinical research conducted.

Page 10: REPUBLIC OF TURKEY PRIME MINISTRY

Technology Development Zones also contribute significantly to research and development of manufacturing industry

One TDZ UnderconstructionMore than one TDZ

• TDZs are organized research centers where universities, research institutions and industrial foundations work

together for innovation and technology transfer; increasing product quality and standards; product development;

commercializing know-how; supporting technological investments and entrepreneurships.

• Every year, 4 new TDZs are opened in Turkey and the goals for 2023 are 5.500 companies, 65.000 employment,

and 10 billion dollars of exports.

• 55% of the firms in TDZs are engaged in Software and Informatics business. Other areas of focus are electronics

and defense industries.

• Number of projects reached 5,717 in April 2013 and total export reached USD 893 million at the end of 2012.

• A total of 322 patents were applied by the firms in TDZs.

• Employment in the TDZs consists of 15,960 R&D and 3,536 support personnel, with a total of 19,496.

Entrepreneurs are exempt from income tax until 2023 over income made from R&D operations and software. Taxes over wages of R&D personnel are exempt until 2023.

50% of the social security premium support for 5 years for R&D personnel will be supported under the law no. 5746 named R&D Operations Support.

Page 11: REPUBLIC OF TURKEY PRIME MINISTRY

Turkish Investment Incentives Programme

The investment incentive program of 2012 comprises 4 different schemes: general, regional, large scale and strategic. Moreover, specific priority investment subjects are supported by measures of Region 5 even they are made in Regions 1, 2, 3 and 4.

All investment types, except the ones that are specifically excluded from investment incentives program, will be supported by General Investment Incentives Program. In this scope, the minimum fixed investment amount is TL 1 million in Region 1 and 2 and TL 500 thousand in Regions 3, 4, 5 and 6.

Support Measures General Inv. Regional Inv. Large Scale Inv. Strategic Inv.

Vat Exception x x x x

Customs Duty Exemption x x x x

Tax Deduction - x x xLand Allocation - x x xInterest Support - x - xVat Refund - - - x

Employer's Social Security Premium Support - x x x

Only For Region 6

Income Tax Withholding Support x x x x

Employee’s Social Security Premium Support - x x x

REGIONAL INVESTMENTS INCENTIVE SCHEME MEASURES

Region OIZ 1 2 3 4 5 6

Tax Reduction (%)Out of OIZ 15 20 25 30 40 50

Within OIZ 20 25 30 40 50 55

Employer's Social Security Premium Support Period (years)

Out of OIZ 2 3 5 6 7 10

Within OIZ 3 5 6 7 10 12

Page 12: REPUBLIC OF TURKEY PRIME MINISTRY

Pharmaceuticals and medical equipment are incentivized

Investments with a minimum amount of 50 million TL are considered as Large Scale Investments.

Strategic investment incentives are given to the production of intermediate and final products with high import dependence with a view to reduce current account deficit. The criteria to gain this support would be: to be made for production of intermediate and final goods with high import dependence of which more than 50% of these goods are supplied by imports, to have a minimum investment amount of TL 50 million, to create minimum 40% value added and to have an import amount of at least USD 50 million for goods to be produced in the last one year period (not applicable to goods with no domestic production).

More specifically, investments in the fields of biotechnological and oncological drugs, and blood products are considered as strategic investments benefiting from the incentives implemented in the fifth region provided that the fixed investment amount is above TL 20 million.

Page 13: REPUBLIC OF TURKEY PRIME MINISTRY

Strategic Plans

The Ministry of Health in its Strategic Plan for period of 2013-2017 is aiming to improve, monitor and evaluate quality standards for pharmaceuticals, biological products and medical devices; to develop, monitor and evaluate standards for medical devices used for treatment purposes; to increase the number of inspections for GMPs; to improve the evaluation of applications and licensing processes and to ensure the rational use of drugs and medical devices.

The Ministry of Science, Industry and Technology has identified strategic goals on its Strategy Paper which are the improvement of regulations to meet the demands of public health and improve investments; the investment on qualified human resource; the improvement of the cooperation among public sector, private sector and universities; effective planning of R&D operations to produce high value added products.

Source: Ministry of Health Strategic Plan 2013-2017

Page 14: REPUBLIC OF TURKEY PRIME MINISTRY

2023 Goals

Selected Key Performance Indicators from Action Plan

Key Performance Indicators Current Status Vision 2023

Innovation Capacity 71. Top 20

The quality of scientific research centers 89. Top 30

Retaining scientists and engineers 35. Top 20

Global Innovation 74. Top 30

Number of new local molecules 0 At least 1

Pharmaceutical R&D expenditures/GDP (2011)* 0.02% 0.1%

Pharmaceutical R&D expenditures/total R&D expenditures (2011)* 0.04% 3.6%

Number of clinical trials conducted throughout a year (2013) 1,267 ≈3600

Pharmaceutical exports as a percentage of pharmaceutical imports (2010)

10% 107%

Number of multinational pharmaceutical companies, that have established regional management centers in Turkey (2011)

3 20

Global Competitiveness 59 Top 25

Ease of doing business (2013) 71 Top 35

Duration of GMP certification (2011) 350 days ‹210 days

Source: AIFD, Vision 2023 Report; Ministry of Scince, Industry and Technology, Turkstat, Deloitte Analysis*: Includes manufacture of basic pharmaceutical products and pharmaceutical preparations

Note: Status is out of 142 counties

Page 15: REPUBLIC OF TURKEY PRIME MINISTRY

HEALTH CAMPUSES

Page 16: REPUBLIC OF TURKEY PRIME MINISTRY

Turkish PPP Program

• Turkey has undertaken an ambitious Healthcare PPP Program through which a total of 35 health campuses and city hospitals are intended to be built using the build-lease-transfer model.

• Each campus will house 2,000 to 4,000 beds divided among general and specialized hospitals and laboratories

• The health campuses and city hospitals will add between 40,000 - 50,000 beds to Turkey’s existing healthcare infrastructure.

• It is estimated that the lease payments for the planned health campuses and city hospitals will be between TL 80,000 and 85,000 per year per bed, amounting to a total of TL 3.2 to 4 billion per year.

• Assuming the MoH will lease the facilities for 25 years, the total amount of lease payments for healthcare campuses and city hospitals will reach TL 80 to 100 billion.

Added Bed Capacity50,000

Planned PPP Projects35

Lease Payments per year

TL 3.2-4 billion

Total Lease PaymentsTL 80 – 100 billion

Average Lease Period25 Years

Current PPP Projects20

• International tenders are being opened for the contracting of each of these hospitals to consortiums (composed of construction companies, architectural designers, operators, and medical technologies companies). The winning consortium of each project will finance the construction and will operate the campus for 25 years against guaranteed annual lease payments to be made by the MoH.

Page 17: REPUBLIC OF TURKEY PRIME MINISTRY

Turkish PPP Program

• 2003-2013 Health Transformation Program

• Vision 2023 • MoH 2013-2017

Strategic Plan• 10th National

Development Plan

• Supreme Planning Board

• MoH, Department of Public Private Partnership

• Under Secretariat of the Treasury

Healthcare PPP Project, build-lease-transfer

• The Supreme Planning Board is involved in a limited number of decisions with fundamental importance, while the MoH assumes bulk of the work to be done for the initiation and realization of Healthcare PPP Projects. The MoH selects relevant PPP projects, prepares feasibility reports and tender documentation. The Under Secretariat of the Treasury, in most cases, procures the land for the PPP project provided that it is determined the land will be treasury-owned land.

• Law no.6428 published in the Official Gazette on 9 March 2013 decreases the burden and risk undertaken by companies involved in PPP projects. It brings legal certainty and introduces a mechanism through which lease payments can be adjusted according to changes in foreign exchange rate.

Legal Framework

Page 18: REPUBLIC OF TURKEY PRIME MINISTRY

Healthcare PPPs in Turkey use the Build-Lease-Transfer (BLT) Model

Under the BLT model, the project company contracts or renews healthcare facilities, and subsequently leases it to the government for a set amount of time. During the contract period, in addition to getting regular lease payments from the government, the project company also has the right to develop and operate non-healthcare facilities. If the company is renewing the facility it receives the right to provide non-healthcare services and a service fee in return for its investment. If new facilities are built the following procedure is followed:

Tender Phase

Build

Lease

Transfer

Projects are awarded through one of the following procedures:

- Open Bid Procedure (preferred) - Open Bid Procedure among bidders selected through a pre-qualification process - Negotiated procedure (only allowed in a limited set of circumstances)

- The project company secures the financing required for the completion of the project.- If the land on which the facility will be built is treasury-owned, MoH arranges for the land to

be used by the project company, free of charge, for the project period.- During the investment period, the transactions between MoH and the company are exempt

from stamp tax.

- Once the health facility is built according to the contracted standard, MoH will lease the facility for a maximum period of 30 years.

- MoH will pay the project company a yearly lease adjusted annually on the basis of the Turkish Producer Price Index and the Turkish Consumer Price Index.

- During this period, the project company also has the right to operate non-healthcare facilities.

- At the end of the contract term, the project company returns the healthcare facilities built to the MoH in good working condition and without any encumbrances.

- If the land on which the facility is developed is not treasury-owned, the MoH takes necessary steps to adequately compensate related parties.

Page 19: REPUBLIC OF TURKEY PRIME MINISTRY

Projects in the Pipeline…

Istanbul Bakırköy Integrated Health Campus 1,043 beds

Istanbul Üsküdar Public Hospital 425 beds

Eskişehir City Hospital 1,060 beds

Kocaeli Integrated Health Campus 1,180 beds

TPHA + TPMDA Campus N/A

Bursa Integrated Health Campus 1,355 beds

Isparta City Hospital 755 beds

Izmir Bayraklı Integrated Health Campus 2,000 beds

Adana Integrated Health Campus 1,539 beds

Elazığ Integrated Health Campus 1,038 beds

Gaziantep Integrated Health Campus 1,867 beds

Konya Karatay Integrated Health Campus 838 beds

Manisa Education and Research Hospital 558 beds

Mersin Integrated Health Campus 1,253 beds

PTR, Psychiatry and High Security Forensic Psychiatry Hospitals

2,400 beds

Yozgat Education and Research Hospital 475 beds

Istanbul İkitelli Integrated Health Campus 2,682 beds

Ankara Bilkent Integrated Health Campus 3,660 beds

Ankara Etlik Integrated Health Campus 3,566 beds

Kayseri Integrated Health Campus 1,583 beds

Pre qualification tender announcement phase

Pre qualification phase

Bid phase

Final Bid phase

Contract phase

Construction phase

Page 20: REPUBLIC OF TURKEY PRIME MINISTRY

THANK YOU